Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers

Acute kidney injury (AKI) remains a deadly condition. Tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein (IGFBP)7 are two recently discovered urinary biomarkers for AKI. We now report on the development, and diagnostic accuracy of two clinical cutoffs for...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation Vol. 29; no. 11; p. 2054
Main Authors: Hoste, Eric A J, McCullough, Peter A, Kashani, Kianoush, Chawla, Lakhmir S, Joannidis, Michael, Shaw, Andrew D, Feldkamp, Thorsten, Uettwiller-Geiger, Denise L, McCarthy, Paul, Shi, Jing, Walker, Michael G, Kellum, John A
Format: Journal Article
Language:English
Published: England 01.11.2014
Subjects:
Acute Kidney Injury - pathology
Acute Kidney Injury - urine
Aged
Biomarkers - urine
Cell Cycle Checkpoints - physiology
Female
Follow-Up Studies
Humans
Insulin-Like Growth Factor Binding Proteins - urine
Male
Middle Aged
Predictive Value of Tests
ROC Curve
Tissue Inhibitor of Metalloproteinase-2 - urine
insulin-like growth factor binding protein (IGFBP)7 and tissue inhibitor of metalloproteinases (TIMP)-2
acute kidney injury
acute renal failure
sensitivity and specificity (MeSH)
biomarkers
ISSN:1460-2385, 1460-2385
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute kidney injury (AKI) remains a deadly condition. Tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein (IGFBP)7 are two recently discovered urinary biomarkers for AKI. We now report on the development, and diagnostic accuracy of two clinical cutoffs for a test using these markers. We derived cutoffs based on sensitivity and specificity for prediction of Kidney Disease: Improving Global Outcomes Stages 2-3 AKI within 12 h using data from a previously published multicenter cohort (Sapphire). Next, we verified these cutoffs in a new study (Opal) enrolling 154 critically ill adults from six sites in the USA. One hundred subjects (14%) in Sapphire and 27 (18%) in Opal met the primary end point. The results of the Opal study replicated those of Sapphire. Relative risk (95% CI) in both studies for subjects testing at ≤0.3 versus >0.3-2 were 4.7 (1.5-16) and 4.4 (2.5-8.7), or 12 (4.2-40) and 18 (10-37) for ≤0.3 versus >2. For the 0.3 cutoff, sensitivity was 89% in both studies, and specificity 50 and 53%. For 2.0, sensitivity was 42 and 44%, and specificity 95 and 90%. Urinary [TIMP-2]•[IGFBP7] values of 0.3 or greater identify patients at high risk and those >2 at highest risk for AKI and provide new information to support clinical decision-making. Clintrials.gov # NCT01209169 (Sapphire) and NCT01846884 (Opal).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1460-2385
1460-2385
DOI:10.1093/ndt/gfu292